S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
All the trading advice you’ve ever received boils down to this (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
All the trading advice you’ve ever received boils down to this (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
All the trading advice you’ve ever received boils down to this (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Behind the tech boom: Big price leaders selectively laying off
All the trading advice you’ve ever received boils down to this (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases

Innovent Biologics Stock Price, News & Analysis (OTCMKTS:IVBXF)

$5.81
0.00 (0.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$5.81
$5.81
50-Day Range
$4.83
$6.30
52-Week Range
$3.55
$6.41
Volume
N/A
Average Volume
4,429 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IVBXF stock logo

About Innovent Biologics Stock (OTCMKTS:IVBXF)

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

IVBXF Stock Price History

IVBXF Stock News Headlines

Innovent's MSCI ESG Rating Upgraded to A
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Innovent Announced China's NMPA Accepts NDA For Taletrectinib
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Innovent Biologics Inc 01801
See More Headlines
Receive IVBXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovent Biologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IVBXF
CIK
N/A
Fax
N/A
Employees
5,144
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. De-Chao Yu Ph.D. (Age 59)
    Co-Founder, Chairman & CEO
    Comp: $4.52M
  • Mr. Hao Xi Ede (Age 64)
    CFO & Executive Director
    Comp: $954.6k
  • Dr. Yong Jun Liu M.D. (Age 54)
    Ph.D., President
  • Dr. Changshou Gao Ph.D.
    Senior VP & CTO
  • Ms. Vivian Zhang
    Chief People Officer
  • Mr. Min Liu
    Chief Commercial Officer
  • Mr. Dongming Wang
    Senior Vice President of Quality
  • Mr. Blake Salisbury
    Senior Vice President of Business Development
  • Ms. Yanju Wang (Age 34)
    Joint Company Secretary
  • Ms. Lok Yee Chan A.C.I.S. (Age 33)
    A.C.S., Joint Company Secretary














IVBXF Stock Analysis - Frequently Asked Questions

Should I buy or sell Innovent Biologics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovent Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IVBXF shares.
View IVBXF analyst ratings
or view top-rated stocks.

How have IVBXF shares performed in 2023?

Innovent Biologics' stock was trading at $4.2850 on January 1st, 2023. Since then, IVBXF stock has increased by 35.6% and is now trading at $5.81.
View the best growth stocks for 2023 here
.

Are investors shorting Innovent Biologics?

Innovent Biologics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,651,800 shares, a decline of 36.2% from the October 31st total of 2,590,000 shares. Based on an average trading volume of 2,700 shares, the short-interest ratio is presently 611.8 days.
View Innovent Biologics' Short Interest
.

How do I buy shares of Innovent Biologics?

Shares of IVBXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:IVBXF) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -